AstraZeneca CEO Pascal Soriot has long argued that shedding some of the company's noncore businesses could help jump-start sales, adding cash to its reservoirs as it chases its lofty sales goals. Now, the British drugmaker is taking another step in that direction as it passes off one of its rare cancer drugs to Sanofi, getting $300 million in the process.
Sanofi's Genzyme is testing an oral drug for Fabry disease, which would go up against its own Fabrazyme if and when it wins approval. But the company knows a thing or two about bringing new pills to market while keeping sales of older drugs intact.
Sanofi's Genzyme is testing an oral drug for Fabry disease, which would go up against its own Fabrazyme if and when it hits the market. But don't worry too much about the pill cannibalizing sales. Judging by the recent success of Genzyme's new oral Gaucher treatment, the company thinks it can find a sizable piece of the Fabry pie for its new pill when the time comes.
Sanofi's rare disease-focused unit Genzyme picked up the FDA's coveted breakthrough-therapy designation for a drug designed to treat a form of Niemann-Pick disease.
Sanofi's rare disease-focused Genzyme picked up the FDA's coveted breakthrough-therapy designation for a candidate designed to treat a form of Niemann-Pick disease.
HBO premiered an award-winning short documentary about Huntington's disease, a rare, hereditary neurological malady, on Monday night. The film follows actress and filmmaker Marianne Palka as she finds out the results of her genetic test. If someone has a parent with the disease as she did, they have a 50/50 chance of getting the disease. The missing voice? Pharma.
Ablynx has entered into a collaboration with Sanofi's Genzyme to investigate the use of its single-domain antibodies against a target involved with multiple sclerosis. The deal gives Genzyme the exclusive right to test the antibodies in models relevant to multiple sclerosis.
Rare disease specialist Genzyme talked up the results of a study published in The Journal of the American Medical Association concluding that the only first-line oral therapy for Gaucher disease reduced spleen size 28% compared to placebo after 9 months.
Three years out, French drugmaker Sanofi continues to reap benefits from having opened a U.S. biologics plant that added capacity for some of the rare disease meds developed by its Genzyme unit.
Sanofi subsidiary Genzyme is tying up with gene therapy upstart Voyager Therapeutics, gambling $100 million upfront on the hot field and promising up to $745 million in milestones for their partnership on a full slate of development programs.